What are the differences between venetoclax and venetoclax, and which patients are they specifically suitable for?

Venetoclax and venetoclax are different names for the same drug, which is mainly used clinically to treat hematological malignancies. Its mechanism of action involves targeting a specific protein calledBCL-2. BCL-2 plays an important role in cell survival, preventing programmed cell death (apoptosis) that leads to the excessive survival of cancerous blood cells. This phenomenon is particularly common in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). By directly binding to BCL-2, venetoclax reopens the cell death switch and triggers apoptosis of cancer cells, thereby achieving therapeutic effects.

Venetoclax is primarily indicated for adult patients, particularly those with chronic lymphocytic leukemia and small lymphocytic lymphoma. By targetingBCL-2, venetoclax can effectively inhibit the proliferation of tumor cells, slow down the development of the disease, and improve the survival rate and quality of life of patients.

Venetoclax also plays an important role in the treatment of small lymphocytic lymphoma. SLL is a manifestation of CLL, and its treatment strategies are similar to CLL. The introduction of venetoclax has given these patients new treatment hope when traditional treatments are ineffective or resistant.

In addition, venetoclax has also shown its unique value in the treatment of acute myeloid leukemia. Particularly for newly diagnosed adult AML patients who are older (75 years and older) or who are not suitable for intensive induction chemotherapy due to comorbidities, venetoclax can be used in combination with lower-intensity chemotherapy drugs (such as azacitidine or decitabine) or low-dose cytarabine (LDAC). This combined treatment model not only reduces the toxic and side effects of treatment, but also helps patients better bear the impact of treatment.

It should be noted that the use of venetoclax is not suitable for all patients. When doctors select indications, they will take into account the patient's overall health status, previous treatment history, and possible comorbidities. For example, in patients with hepatic impairment, the dose of venetoclax may need to be adjusted to avoid potential toxic side effects. In addition, during the treatment process, changes in the patient's hematological parameters also need to be closely monitored to ensure the safety of the treatment. Venetoclax may cause platelet and neutropenia, so regular blood tests are necessary.

In summary, venetoclax (venetoclax), as a new targeted drug, provides innovative treatment options for patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and acute myeloid leukemia. Through detailed analysis of the patient's condition and individualized treatment plans, doctors can give full play to the therapeutic potential of venetoclax and improve the patient's quality of life.

References:

https://www.drugs.com/newdrugs/genentech-announces-fda-grants-venclexta-accelerated-approval-newly-diagnosed-acute-myeloid-4870.html

xa0